LENSAR, INC. Research and Development Expense
LENSAR, INC. (LNSR) reported Research and Development Expense of $1.27 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-13
- LENSAR, INC. research and development expense for the quarter ending 2026-06-30 was $1.27M, a 10.67% decline year-over-year.
- LENSAR, INC. research and development expense for the quarter ending 2026-03-31 was $1.39M, a 9.71% decline year-over-year.
- LENSAR, INC. research and development expense for the quarter ending 2025-12-31 was $1.30M, a 2.92% decline year-over-year.
- LENSAR, INC. research and development expense for the quarter ending 2025-09-30 was $1.37M, a 13.73% increase year-over-year.
- LENSAR, INC. research and development expense for fiscal 2025 was $5.62M, a 5.50% increase from fiscal 2024.
- LENSAR, INC. research and development expense for fiscal 2024 was $5.33M, a 13.19% decline from fiscal 2023.
- LENSAR, INC. research and development expense for fiscal 2023 was $6.14M, a 48.04% decline from fiscal 2022.
- LENSAR, INC. research and development expense for fiscal 2022 was $11.81M, a 4.40% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.27M 10-Q · filed 2026-08-13 | $2.66M 10-Q · filed 2026-08-13 | $3.95M derived: sum of 3 quarters · filed 2026-08-13 | $5.32M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $1.39M 10-Q · filed 2026-05-08 | $2.68M derived: sum of 2 quarters · filed 2026-05-08 | $4.05M derived: sum of 3 quarters · filed 2026-05-08 | $5.47M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $2.66M derived: sum of 2 quarters · filed 2026-03-31 | $4.09M derived: sum of 3 quarters · filed 2026-08-13 | $5.62M 10-K · filed 2026-03-31 |
| 2025-09-30 | $1.37M 10-Q · filed 2025-11-06 | $2.79M derived: sum of 2 quarters · filed 2026-08-13 | $4.33M 10-Q · filed 2025-11-06 | $5.66M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $1.43M 10-Q · filed 2026-08-13 | $2.96M 10-Q · filed 2026-08-13 | $4.29M derived: sum of 3 quarters · filed 2026-08-13 | $5.50M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $1.53M 10-Q · filed 2026-05-08 | $2.87M derived: sum of 2 quarters · filed 2026-05-08 | $4.07M derived: sum of 3 quarters · filed 2026-05-08 | $5.42M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $1.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $2.54M derived: sum of 2 quarters · filed 2026-03-31 | $3.88M derived: sum of 3 quarters · filed 2026-03-31 | $5.33M 10-K · filed 2026-03-31 |
| 2024-09-30 | $1.20M 10-Q · filed 2025-11-06 | $2.55M derived: sum of 2 quarters · filed 2025-11-06 | $3.99M 10-Q · filed 2025-11-06 | $5.46M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $1.35M 10-Q · filed 2025-08-07 | $2.79M 10-Q · filed 2025-08-07 | $4.25M derived: sum of 3 quarters · filed 2025-08-07 | $5.78M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $1.44M 10-Q · filed 2025-05-08 | $2.91M derived: sum of 2 quarters · filed 2025-05-08 | $4.43M derived: sum of 3 quarters · filed 2025-05-08 | $5.93M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $1.46M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $2.99M derived: sum of 2 quarters · filed 2025-02-27 | $4.49M derived: sum of 3 quarters · filed 2025-02-27 | $6.14M 10-K · filed 2025-02-27 |
| 2023-09-30 | $1.53M 10-Q · filed 2024-11-07 | $3.03M derived: sum of 2 quarters · filed 2024-11-07 | $4.68M 10-Q · filed 2024-11-07 | $6.29M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $1.50M 10-Q · filed 2024-08-08 | $3.15M 10-Q · filed 2024-08-08 | $4.76M derived: sum of 3 quarters · filed 2024-08-08 | $6.34M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $1.65M 10-Q · filed 2024-05-09 | $3.27M derived: sum of 2 quarters · filed 2024-05-09 | $4.84M derived: sum of 3 quarters · filed 2024-05-09 | $8.68M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $1.61M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-04 | $3.19M derived: sum of 2 quarters · filed 2024-03-04 | $7.03M derived: sum of 3 quarters · filed 2024-03-04 | $11.81M 10-K · filed 2024-03-04 |
| 2022-09-30 | $1.58M 10-Q · filed 2023-11-09 | $5.41M derived: sum of 2 quarters · filed 2023-11-09 | $10.20M 10-Q · filed 2023-11-09 | $13.62M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $3.83M 10-Q · filed 2023-08-09 | $8.62M 10-Q · filed 2023-08-09 | $12.04M derived: sum of 3 quarters · filed 2023-08-09 | $15.23M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $4.79M 10-Q · filed 2023-05-15 | $8.21M derived: sum of 2 quarters · filed 2023-05-15 | $11.39M derived: sum of 3 quarters · filed 2023-05-15 | $14.40M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $3.42M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $6.61M derived: sum of 2 quarters · filed 2023-03-16 | $9.61M derived: sum of 3 quarters · filed 2023-03-16 | $12.36M 10-K · filed 2023-03-16 |
| 2021-09-30 | $3.18M 10-Q · filed 2022-11-09 | $6.19M derived: sum of 2 quarters · filed 2022-11-09 | $8.94M 10-Q · filed 2022-11-09 | $11.48M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $3.01M 10-Q · filed 2022-08-08 | $5.75M 10-Q · filed 2022-08-08 | $8.29M derived: sum of 3 quarters · filed 2022-08-08 | $10.30M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $2.75M 10-Q · filed 2022-05-09 | $5.29M derived: sum of 2 quarters · filed 2022-05-09 | $7.29M derived: sum of 3 quarters · filed 2022-05-09 | $8.73M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $2.54M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $4.55M derived: sum of 2 quarters · filed 2022-03-03 | $5.98M derived: sum of 3 quarters · filed 2022-03-03 | $7.55M 10-K · filed 2022-03-03 |
| 2020-09-30 | $2.00M 10-Q · filed 2021-11-08 | $3.44M derived: sum of 2 quarters · filed 2021-11-08 | $5.01M 10-Q · filed 2021-11-08 | $6.42M derived: sum of 4 quarters · filed 2021-11-08 |
| 2020-06-30 | $1.43M 10-Q · filed 2021-08-06 | $3.00M 10-Q · filed 2021-08-06 | $4.42M derived: sum of 3 quarters · filed 2021-08-06 | $8.75M derived: sum of 4 quarters · filed 2021-08-06 |
| 2020-03-31 | $1.57M 10-Q · filed 2021-05-06 | $2.98M derived: sum of 2 quarters · filed 2021-05-06 | $7.31M derived: sum of 3 quarters · filed 2021-05-06 | |
| 2019-12-31 | $1.41M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | $5.74M derived: sum of 2 quarters · filed 2021-03-12 | $7.57M 10-K · filed 2021-03-12 | |
| 2019-09-30 | $4.33M 10-Q · filed 2020-11-12 | $6.16M 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SkinHealth Systems Inc. (SKIN) | United States | $0.086B | -3.17 |
| Microbot Medical Inc. (MBOT) | $0.089B | -7.97 | |
| Pulmonx Corp (LUNG) | United States | $0.082B | -1.16 |
| RenovoRx, Inc. (RNXT) | United States | $0.076B | -3.62 |
| FRACTYL HEALTH, INC. (GUTS) | United States | $0.075B | -1.18 |
| CVRx, Inc. (CVRX) | United States | $0.067B | -2.62 |
| DarioHealth Corp. (DRIO) | $0.066B | -1.39 | |
| TELA Bio, Inc. (TELA) | United States | $0.057B | -0.82 |
| Apyx Medical Corp (APYX) | United States | $0.120B | -21.85 |
| Xtant Medical Holdings, Inc. (XTNT) | United States | $0.053B |